WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016088838) PURINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/088838    International Application No.:    PCT/JP2015/084028
Publication Date: 09.06.2016 International Filing Date: 03.12.2015
IPC:
C07D 473/18 (2006.01), A61K 31/522 (2006.01), A61P 11/00 (2006.01), A61P 13/02 (2006.01), A61P 25/04 (2006.01), A61P 43/00 (2006.01)
Applicants: SHIONOGI & CO., LTD. [JP/JP]; 1-8, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 5410045 (JP)
Inventors: ICHIHASHI, Yusuke; (JP)
Agent: YAMAUCHI, Hideaki; (JP)
Priority Data:
2014-245822 04.12.2014 JP
Title (EN) PURINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF
(FR) DÉRIVÉ DE PURINE ET COMPOSITION PHARMACEUTIQUE LE CONTENANT
(JA) プリン誘導体およびその医薬組成物
Abstract: front page image
(EN)The present invention provides a compound having a novel P2X3 and/or P2X2/3 receptor antagonizing effect. A compound represented by formula (I): (in the formula, R1a is an optionally substituted alkyl or the like, R1b is a hydrogen atom or the like, R2 is an optionally substituted aromatic carbocyclic group or the like, R3 is an optionally substituted aromatic carbocyclic group or the like, R4a are each independently a hydrogen atom or the like, R4b are each independently a hydrogen atom or the like, n is an integer of 0-4, X is -N(R5)- or the like, R5 is a hydrogen atom or the like), or a pharmacologically acceptable salt thereof.
(FR)La présente invention concerne un composé ayant un nouvel effet antagoniste des récepteurs P2X3 et/ou P2X2/3. L'invention concerne un composé représenté par la formule (I) : (dans la formule, R1a est un alkyle facultativement substitué ou similaire, R1b est un atome d'hydrogène ou similaire, R2 est un groupe carbocyclique aromatique facultativement substitué ou analogue, R3 est un groupe carbocyclique aromatique facultativement substitué ou analogue, R4asont chacun indépendamment un atome d'hydrogène ou analogue, les R4b sont chacun indépendamment un atome d'hydrogène ou analogue, n est un nombre entier de 0 à 4, X est -N(R5) ou similaire, R5 est un atome d'hydrogène ou analogue), ou un sel pharmacologiquement acceptable de celui-ci.
(JA) 本発明は、新規なP2X3および/またはP2X2/3受容体拮抗作用を有する化合物を提供する。 式(I):(式中、R1aは置換若しくは非置換のアルキル等、R1bは水素原子等、Rは置換若しくは非置換の芳香族炭素環式基等、Rは置換若しくは非置換の芳香族炭素環式基等、R4aはそれぞれ独立して水素原子等、R4bはそれぞれ独立して水素原子等、nは0~4の整数、Xは-N(R)-等、Rは水素原子等)で示される化合物またはその製薬上許容される塩。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)